MT95-4, a fully humanized antibody raised against aminopeptidase N, reduces tumor progression in a mouse model.
Bottom Line: To develop a novel monoclonal antibody-based cancer therapy targeting APN/CD13, we established a fully humanized anti-APN/CD13 monoclonal antibody, MT95-4.We found that expression of human APN/CD13 in murine melanoma cells increased the size of subcutaneous tumors, extent of lung metastasis and degree of angiogenesis in the subcutaneous tumors; these tumor-promoting and angiogenesis-promoting characteristics were reduced by the i.p. administration of MT95-4.These results suggested that the antitumor and anti-angiogenic effects of MT95-4 were dependent on APN/CD13 expression in tumor cells.
Affiliation: Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.Show MeSH
Related in: MedlinePlus
Mentions: We established two B16-F1-derived cell lines that differed in the expression levels of human APN/CD13 (control-B16 and APN-B16 cells). Quantitative real-time PCR and flow cytometric analysis revealed that APN-B16 cells expressed high levels of human APN/CD13, while control-B16 cells did not (Fig.2a,b). When the in vitro cell proliferation rates of the two cell lines were compared, no differences were observed (data not shown).
Affiliation: Department of Molecular and Internal Medicine, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.